QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: PSUR Single Assessment and EU Procedures

Test your understanding of the concepts covered by GVP Module VII: PSUR Single Assessment and EU Procedures.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should a company maintain an accurate record of the relevant assessor and procedural roles for each PSUSA rather than rely on historical assumptions?

Because assessor roles and regulatory arrangements may differ by procedure and change over time Because the assessor becomes the legal MAH during the procedure Because previous PSURs are invalid if the assessor changes Because only historical procedural information is accepted in a PSUR

Question 2 of 10 After a change in MAH, which information is most important for pharmacovigilance and regulatory continuity?

Only the commercial transfer agreement Only the most recent PSUR submission receipt PSUR and PSUSA history, open commitments, safety concerns, RMP status, product-information changes and outstanding actions Only the previous MAH’s organisational chart

Question 3 of 10 Which activity should generally occur before substantive PSUR preparation begins?

Close all existing signals related to the active substance Establish the applicable regulatory scope, reporting interval, DLP, products and submission route Implement any anticipated product-information changes Obtain agreement from every other MAH on the scientific conclusions

Question 4 of 10 Which issue is most characteristic of validation or procedural completeness rather than substantive scientific assessment?

Whether a newly observed event changes the benefit-risk balance Whether risk-minimisation measures are effective Whether the correct reporting interval, DLP, format and required documents were submitted Whether the clinical importance of a signal differs by indication

Question 5 of 10 What is the operational significance of using the current EURD information when planning a PSUR?

It determines the MAH’s final scientific conclusions automatically It provides information relevant to periodic-reporting obligations, including reference dates and frequencies It replaces the need to verify the applicable regulatory procedure It determines whether a product’s benefit-risk balance is favourable

Question 6 of 10 What is the most significant governance risk when Regulatory Affairs considers a PSUSA action complete but Pharmacovigilance considers it open?

The organisation may have inconsistent cross-functional understanding of requirements, ownership, deadlines and completion criteria The PSUR must automatically be withdrawn The active substance must be removed from the EURD framework The disagreement proves that the scientific assessment was invalid

Question 7 of 10 A company submits a PSUR that contains a well-supported conclusion that no new action is needed. What should the company expect next?

The submission automatically becomes the final regulatory conclusion The report may undergo independent assessment, which could agree, disagree, identify uncertainty or request clarification The report is returned because regulators cannot assess MAH conclusions No further process is required unless another MAH objects

Question 8 of 10 Which statement best captures the relationship between coordinated assessment and product-level implementation?

A coordinated EU assessment means that one implementation action always covers every product Coordinated assessment promotes consistency, but each MAH must determine and document how the outcome applies to its own authorisations Implementation is performed only by PRAC because it issued the scientific recommendation Product-level implementation is unnecessary when products share an active substance

Question 9 of 10 What is the principal regulatory rationale for assessing relevant products containing the same active substance through a single-assessment approach?

To eliminate the need for each MAH to maintain its own pharmacovigilance system To ensure that all products have identical indications and product information To reduce duplication and promote consistent interpretation of common safety information To transfer responsibility for the PSUR from MAHs to national competent authorities

Question 10 of 10 How should a significant non-EU regulatory action concerning the same safety issue generally be handled in the EU PSUR process?

It should automatically determine the EU regulatory outcome It should be ignored because only EU evidence is relevant Its underlying evidence and rationale should be evaluated as potentially relevant safety information, while the EU framework remains governing It should replace the PSUSA assessment if the foreign authority acted first

Knowledge Assessment: PSUR Single Assessment and EU Procedures

Cookie Settings